Cybin’s lead psychedelic-based candidate CYB003, designed as an adjunctive treatment for major depressive disorder (MDD), is making headway towards commercialisation with a two-pronged strategy: robust clinical development and strategic infrastructure partnerships.

In a recent move, the company partnered with Osmind, a point-of-care software provider whose network spans over 800 interventional psychiatry clinics. Doug Drysdale, CEO of Cybin, says the collaboration will be key in building commercial momentum ahead of potential FDA approval.

“The partnership with Osmind enhances our commercial strategy by leveraging its extensive clinic network,” Drysdale explains. “CYB003 will be well-positioned for market access, streamlining pharmacy fulfillment, patient engagement, and reimbursement pathways while supporting physician adoption.”

Osmind’s clinic footprint, covering a broad swath of interventional psychiatry providers, offers the kind of early infrastructure needed to accelerate post-approval uptake. Drysdale notes:

“This established network can significantly enhance adoption, especially with early engagement from clinicians and payers that supports scalability.”

Growing a nationwide trial network

Cybin has made rapid progress in clinical development, already activating 18 sites for its Phase 3 program, known as Paradigm. The first pivotal study, Approach, aims to expand to around 45 clinical sites.

“Every clinical site comes with operational and logistical complexity,” Drysdale acknowledges. “Our Strategic Partnership Agreements help to streamline those logistics—essentially expediting the timeline from engagement to enrolment.”

The ability to scale site activation directly impacts recruitment efficiency and allows Cybin to maintain clinical momentum as it eyes broader rollout.

Breakthrough remission rates drive momentum

CYB003 made headlines earlier this year following Phase 2 data that showed 71% of patients experienced remission for up to 12 months after just two doses.

“This data reinforces the potential of CYB003 as a breakthrough therapy,” Drysdale says. “If similar efficacy is shown in pivotal trials, and we receive FDA approval, we believe CYB003 will be considered much earlier in the treatment paradigm for depression.”

Crucially, Drysdale sees the therapy as a potential cost-saver in psychiatric care by reducing the need for hospitalisations and long-term drug dependency—an attractive proposition for payers navigating budget constraints.

Designed for integration with standard MDD care

While many psychedelic therapies have required patients to discontinue other medications, CYB003 was specifically developed to be adjunctive—a feature that could ease integration into routine clinical practice.

“When we launched our Phase 2 trial, conventional thinking was to remove participants from medications targeting similar receptor pathways,” Drysdale explains. “But based on our own research, we pursued an adjunctive approach. Our data—and that from third-party studies—now suggests there’s real value in keeping patients on existing therapy going into treatment.”

This design element could make CYB003 more attractive to prescribers and potentially faster to deploy once on the market.

Two pivotal trials: Approach and Embrace

Cybin is planning two large Phase 3 studies: the ongoing Approach trial and Embrace, set to launch in mid-2025. Both are designed to assess the safety and efficacy of CYB003, but Embrace includes an important tweak: an intermediate dose arm.

“Approach is a 220-person study with active and placebo arms,” Drysdale explains. “Embrace will expand to 330 participants and include active, placebo, and intermediate doses. The latter introduces an 8mg arm—half the 16mg active dose.”

This intermediate arm is designed to reduce expectancy bias, a known challenge in psychedelic research. According to Drysdale:

“It helps maintain blinding integrity, as participants experiencing mild psychedelic effects are less certain about whether they received the active treatment or placebo. That’s important for achieving scientifically robust outcomes.”

Preparing for regulatory approval and reimbursement

CYB003 was granted Breakthrough Therapy designation by the FDA—a status that allows for enhanced collaboration during the approval process. But Cybin is also laying the groundwork for post-approval access by working closely with payers and providers.

“Reimbursement will be a key driver of access,” Drysdale says. “We’re engaging stakeholders across the care continuum to optimise delivery and better understand what value looks like to each group.”

He adds that health economics and outcomes research (HEOR) will play a pivotal role in demonstrating CYB003’s value to payers and regulators, particularly as the therapy moves closer to market.

Real-world data to reinforce evidence

Cybin’s partnership with Osmind may also pay dividends after CYB003 reaches the market. Osmind’s platform captures real-world data across its clinic network, offering the potential to bolster payer confidence and support ongoing adoption.

“Real-world data from Osmind could accelerate post-approval adoption by demonstrating treatment effectiveness in clinical settings,” Drysdale explains. “It will support physician confidence, payer decisions, and broader market acceptance.”

Differentiated by novel science and execution

As more psychedelic drug developers reach clinical stage, Cybin sees its scientific and strategic differentiation as a competitive edge.

“Rather than delivering naturally occurring compounds, we’ve focused on creating novel molecules and optimised formulations,” says Drysdale. “Our goal is to improve key characteristics—onset, duration, consistency—that matter to both patients and providers.”

Navigating the hurdles ahead

While the field is evolving rapidly, challenges remain in bringing psychedelic therapies into the mainstream. Drysdale points to three main areas: navigating controlled substance regulations, educating providers, and securing reimbursement.

“We believe CYB003—if approved—can be accessible, scalable, and cost-effective within modern psychiatric care,” he concludes. “But success will depend on clearing these hurdles through proactive engagement, rigorous science, and patient-centred thinking.”